RP2
Phase 2Biologic
RP2 is one of 91 biologic programs targeting Uveal Melanoma. It is currently in Phase 2.
2
Indications
6
Total Trials
5
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
95 competitors in Esophageal Adenocarcinoma
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Taxol
TevaPhase 3
Lenvima
EisaiPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Paraplatin
AAvyxa
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Taxotere
AAvyxa
Phase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Keytruda
Merck & Co.Phase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Uveal Melanoma1 trial
High-Risk Oral Precancerous Disease1 trial
Esophageal Adenocarcinoma1 trial
Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
Not yet recruiting·—·Phase 2·NCT07059611·34 enrolled
Bevacizumab1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RP2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- RReplimune Inc.